How much weight do people typically lose on Wegovy after 3 months?

What does the trial data show for the three-month period specifically?

The STEP 1 trial, published in the New England Journal of Medicine, is the most widely cited evidence for semaglutide 2.4mg. It ran for 68 weeks and reported roughly 15% average weight loss across that full period. The three-month window is not a formal reporting endpoint in STEP 1, but researchers and clinicians generally describe an early-phase response in the region of 5–9% by week 12.

Why the wide range? Because three months still sits inside the titration phase for most people. Wegovy starts at 0.25mg weekly and steps up approximately every four weeks (0.25mg, 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg) so at the 12-week mark many patients have only recently reached 1.0mg. The medicine is doing more work as each month passes, which is why the six-month picture tends to look considerably more pronounced than the three-month one.

People who tolerate increases well and move through the schedule without extended pauses often see results closer to the higher end of that early range. Those who need to slow down at a particular dose (which is perfectly normal and clinically appropriate) may find their three-month total is more modest, with the bulk of their progress arriving later. That is not a sign the treatment is failing; it is the schedule working as designed.

How does the three-month figure compare to what happens earlier and later on?

The first four weeks tend to produce the smallest loss, partly because the starting dose is there primarily to help your body adjust rather than drive significant weight change. Our breakdown of the first month on Wegovy explains why that period often surprises people who expect immediate, dramatic results.

By contrast, months three through six are where many people notice the most consistent week-on-week progress. The dose is higher, appetite suppression is more established, and the early gastrointestinal side effects that can limit food intake in unpredictable ways have usually settled. The NHS patient information for semaglutide notes that nausea and related effects are typically most pronounced around dose increases and tend to ease afterwards, which means month three often coincides with a more comfortable, more productive phase of treatment.

Looking further out, data from the full STEP 1 trial period suggest that meaningful weight loss continues well beyond six months for most participants. Our page covering overall Wegovy results places the three-month snapshot into the longer arc of how the medicine works over time. The short version: three months is a real and encouraging start, not the destination.

Does the new 7.2mg pen change the picture for people starting Wegovy now?

Possibly, yes, eventually. The MHRA approved a dedicated single-dose 7.2mg Wegovy pen on 14 April 2026, offering a higher maintenance dose for eligible adults with a BMI of 30 or above. Trial data for 7.2mg semaglutide reported average weight loss of around 20.7% over 72 weeks, which closes the gap significantly with the results seen in tirzepatide trials.

What does that mean for a three-month timeline? Practically very little, because the titration schedule remains the same regardless of the eventual ceiling. You still begin at 0.25mg and work upward at the pace your body tolerates. The pen that might be sitting in your fridge door at the 12-week mark is almost certainly not your maintenance dose, it is part of a carefully managed progression. If you're curious about how long Wegovy takes to build momentum, the short answer is that the medicine rewards patience, and three months is early in a process that typically runs for a year or more.

It is also worth noting that the 7.2mg pen is approved specifically for weight management in adults with a BMI of 30 or above, not for the cardiovascular indication. Availability of specific dose formats is confirmed at the point of clinical assessment. For a broader overview of the treatment and what it involves, our Wegovy treatment page covers the full picture.

What actually shapes how much weight someone loses in the first three months?

Three factors tend to matter most. The first is how quickly a person tolerates dose escalation, slower titration means a lower average dose across the first 12 weeks, which moderates early results. The second is starting weight: in proportional terms, someone with a higher starting BMI may see a similar percentage loss to someone with a lower BMI, even if the absolute number on the scales looks very different. The third is lifestyle: Wegovy is licensed alongside a reduced-calorie diet and increased physical activity, and the trial data behind it was generated under those conditions. The medicine changes hunger signals; the choices made within that changed appetite determine the pace of progress.

There is also the question of which conditions someone is managing alongside their weight. People with type 2 diabetes, for example, often lose weight more slowly on GLP-1 medicines than those without, this is well documented in the STEP trials and worth knowing before setting expectations. A prescriber who knows your full health picture can help you set a realistic three-month target and adjust if things are moving differently to expected. If questions about costs have factored into your thinking, our Wegovy cost page explains what private treatment typically involves. When you're ready to find out whether Wegovy suits your situation, you can start your free consultation with our clinical team.